{"entity":{"id":"shenzhen-targetrx","kind":"company","name":"Shenzhen TargetRx","aka":["Shenzhen TargetRx Co., Ltd."],"tldr":"Shenzhen TargetRx is a China-based biotechnology company running 4 late-stage cancer trials of TGRX-326, TGRX-814 and TGRX-678 in non-small-cell lung cancer, hodgkin lymphoma and acute myeloid leukaemia.","summary":"Shenzhen TargetRx, based in Shenzhen, China, is a biotechnology company. TargetRx develops next-generation targeted small-molecule anticancer drugs designed to overcome drug resistance, using an AI-assisted, structure-based molecular design platform. On ClinicalTrials.gov it is the lead sponsor of 4 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing TGRX-326, TGRX-814 and TGRX-678 in non-small-cell lung cancer, hodgkin lymphoma, acute myeloid leukaemia, acute lymphoblastic leukaemia and myelodysplastic syndromes / neoplasms. The largest, NCT06082635 (TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)), plans to enrol 321 participants (actual). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.tjrbiosciences.com"},{"label":"ClinicalTrials.gov: trials led by Shenzhen TargetRx","url":"https://clinicaltrials.gov/search?lead=Shenzhen%20TargetRx%20Co.%2C%20Ltd."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc","hodgkin-lymphoma","aml","all-leukemia","mds","cml"],"sections":[],"technologies":[],"targets":[],"drugs":["tgrx-326"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05955391","nct06453902","nct06206174"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Shenzhen","country":"CN","companyType":"biotech","website":"https://www.tjrbiosciences.com","investors":[],"funding":[]},"route":"/companies/shenzhen-targetrx/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"cml","kind":"cancer","name":"Chronic myeloid leukaemia (CML)","route":"/cancers/cml/"},{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"},{"id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"tgrx-326","kind":"drug","name":"TGRX-326","route":"/drugs/tgrx-326/"}],"trial":[{"id":"nct05955391","kind":"trial","name":"TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC)","route":"/trials/nct05955391/"},{"id":"nsclc-3","kind":"trial","name":"TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)","route":"/trials/nsclc-3/"},{"id":"nct06453902","kind":"trial","name":"TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients","route":"/trials/nct06453902/"},{"id":"nct06206174","kind":"trial","name":"TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies","route":"/trials/nct06206174/"}]}}